LSTA
LISATA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.02
+0.99%Year over year
Reported trailing growth
- Revenue
- -90.7%
- EBITDA
- +21.8%
- EBIT
- +21.8%
- EPS
- +26.5%
- Free cash flow
- +25.1%
- Operating cash flow
- +24.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -83.0%
- EBITDA
- +15.6%
- EBIT
- +18.7%
- Net income
- +17.0%
- EPS
- +20.4%
- Free cash flow
- +17.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026